Skip to main content

11 Result(s)

within Article Remove this filter Susan O'Brien Remove this filter Hematology Remove this filter

and

  1. Article

    Open Access

    Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

    Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential b...

    Hagop Kantarjian, Fadi G. Haddad, Nitin Jain… in Journal of Hematology & Oncology (2023)

    Download PDF (1171 KB) View Article

  2. No Access

    Article

    Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

    Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previo...

    Nitin Jain, Philip Thompson, Jan Burger, Alessandra Ferrajoli, Koichi Takahashi… in Leukemia (2021)

  3. No Access

    Article

    Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

    Jennifer R. Brown, Andrew Zelenetz, Richard Furman, Nicole Lamanna… in Leukemia (2020)

  4. Article

    Open Access

    Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

    Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy an...

    Daniel J. DeAngelo, Anjali S. Advani, David I. Marks… in Blood Cancer Journal (2020)

    Download PDF (613 KB) View Article

  5. No Access

    Article

    Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

    Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of develo** second cancers; we aimed to evaluat...

    Koji Sasaki, Hagop M. Kantarjian, Susan O’Brien… in International Journal of Hematology (2019)

  6. No Access

    Article

    Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

    Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in vitro to ...

    Kiran Naqvi, Jorge E. Cortes, Raja Luthra… in International Journal of Hematology (2018)

  7. No Access

    Article

    Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies

    The outcomes in adult B-cell acute lymphoblastic leukemia (ALL) remain inferior to those achieved in pediatric populations. Targeted therapy with monoclonal antibodies may improve outcomes in adult B-cell ALL ...

    Naval Daver, Susan O’Brien in Current Hematologic Malignancy Reports (2013)

  8. No Access

    Article

    Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

    The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutive...

    Michael S. Mathisen, Susan O’Brien… in Current Hematologic Malignancy Reports (2011)

  9. No Access

    Article

    Survival Advantage in CLL with Frontline FCR Therapy

    Susan O’Brien in Current Hematologic Malignancy Reports (2011)

  10. No Access

    Article

    Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?

    Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable progno...

    Deborah A. Thomas, Susan O’Brien, Stefan Faderl… in Current Hematologic Malignancy Reports (2011)

  11. No Access

    Article

    Novel therapies for relapsed acute lymphoblastic leukemia

    The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor. Salvage therapy mimics regimens with activity in newly diagnosed ALL. Novel strategies under investigation as monoth...

    Amber Fullmer, Susan O’Brien, Hagop Kantarjian… in Current Hematologic Malignancy Reports (2009)